World Mosquito Program Noumea - Human Sample Component

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-25

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The dengue, Zika and chikungunya arboviruses represent potentially severe infections to which the New Caledonian population is exposed. In the absence of specific treatment or vaccine, vector control remains the method of choice to limit their spread. However, the traditional methods of prevention and vector control measure today face their limits: mosquito resistance to insecticides, difficulty of access and destruction of breeding areas... The World Mosquito Program Noumea project is based on the artificial colonization of the mosquito vector Aedes aegypti by the endosymbiotic bacteria Wolbachia, which reduces its ability to transmit arboviruses. The breeding of mosquitoes carrying the bacterium Wolbachia in the laboratories of the Institut Pasteur of New Caledonia requires the use of human blood samples for mosquito gorging.

The objective of the research is to generate, maintain and amplify Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria for the planned insect release program in Noumea.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Virological and Immunological Determinants of Arbovirus Infection in New Caledonia

NCT04619823

Arbovirus Infections Zika Dengue +1 more

RECRUITING NA

Cohort of Patients Infected by an Arbovirus

NCT01099852

Fever Dengue Chikungunya +1 more

UNKNOWN

Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in Mali

NCT02206451

Malaria

COMPLETED

Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia

NCT04615364

Arbovirus Infections Dengue Zika +1 more

RECRUITING

Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia

NCT03631719

Dengue Chikungunya Virus Infection Zika Virus Infection

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The dengue, Zika and chikungunya arboviruses represent potentially severe infections to which the New Caledonian population is exposed. In the absence of specific treatment or vaccine, disease vector control remains the method of choice to limit their spread. However, the traditional methods of prevention and disease vector control must today face their limits: mosquito resistance to insecticides, difficulty of access and destruction of breeding areas... The World Mosquito Program Noumea project is based on the artificial colonization of the mosquito vector Aedes aegypti by the endosymbiotic bacterium Wolbachia, which reduces its ability to transmit arboviruses. The breeding of mosquitoes carrying the bacterium Wolbachia in the laboratories of the Institut Pasteur of New Caledonia requires the use of human blood samples for mosquito gorging.

The objective of the research is to generate, maintain and amplify Aedes aegypti Caledonian lineages carrying the bacterium Wolbachia for the planned insect release program in Noumea.

The establishment of Wolbachia in Aedes aegypti populations in Noumea should lead to the reduction of active transmission of dengue, Zika and chikungunya in the municipality.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arbovirus Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hemochromatosis or polycythemia patients

Blood samples from hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.

Blood bag (volume of blood: from 450 to 500 mL).

Blood donations of hemochromatosis or polycythemia patients

Intervention Type OTHER

Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.

Healthy donors

Blood samples from healthy donors. Blood bag (volume of blood: from 450 to 500 mL).

Blood donations of healthy donors

Intervention Type OTHER

Blood samples are from blood donations of healthy donors.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood donations of hemochromatosis or polycythemia patients

Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.

Intervention Type OTHER

Blood donations of healthy donors

Blood samples are from blood donations of healthy donors.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All adult hemochromatosis or polycythemia patients or healthy donors have given their written consent to participate in the study and for the collection of a blood sample.

Exclusion Criteria

* Participation refusal
* Minor person
* Positive result by Reverse transcription polymerase chain reaction RT-PCR for arboviruses
* Invalid qualification of the blood donation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes